Infectious Disease Platform
Capacity
- Comprehensive virus, bacteria, fungi coverages
- Supporting drug and vaccine discovery from early research to clinical trials
Capability
- 20+ various viruses
- Supporting discovery of antivirals and vaccines, including HBV, SARS-CoV,
IFV, RSV, HCV, HIV, EV71, herpes, rabies, and other viruses - 130+ different bacterial and fungal species
- Supporting discovery of antibacterial and antifungal therapeutics, including ESKAPE,
Streptococcus, Neisseria, H. influenza, Anaerobes, H. pylori, Mycoplasma, and more - Opsonophagocytic assays: S. pneumoniae
Clinical Bioanalysis Platform
- Molecular Testing Laboratory recognized with accreditation from CAP
- Successfully cleared every CAP inspection; flawlessly passed all inspections from NMPA/FDA
- Achieved one-time passing in proficiency testing (HBV DNA and HCV RNA viral load, UGT1A1 genotyping) endorsed by CAP, SCCL, and NCCL
- Expertise in clinical virology, oncolytic virus pharmacokinetics (PK) and pharmacodynamics (PD), vaccine immune response analysis, cell therapy
PK and PD assessments, AAV therapy, and advanced therapeutics
Infectious Disease Platform_Flyer
Related Content
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are globally prevalent human pathogens associated with a wide range of...
VIEW RESOURCETuberculosis is the leading cause of death from an infectious disease and is caused by Mycobacterium tuberculosis (MTB). Inosine-5′-monophosphate dehydrogenase...
VIEW RESOURCE